Pallas Capital Advisors LLC Makes New $663,000 Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Pallas Capital Advisors LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,203 shares of the biopharmaceutical company’s stock, valued at approximately $663,000.

A number of other hedge funds have also recently made changes to their positions in ALNY. MV Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $25,000. HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $27,000. Golden State Wealth Management LLC boosted its stake in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $29,000. Finally, Manchester Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 72 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $242.61 on Thursday. The company has a market cap of $32.46 billion, a price-to-earnings ratio of 45.09 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $495.55. The stock’s 50 day simple moving average is $269.15 and its two-hundred day simple moving average is $298.51. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the prior year, the company earned ($0.51) EPS. The company’s quarterly revenue was up 66.9% compared to the same quarter last year. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares in the company, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ALNY shares. Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. BMO Capital Markets started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday. They set an “outperform” rating and a $318.00 target price for the company. Bank of America cut their target price on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Morgan Stanley reduced their price target on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a report on Friday, July 31st. Finally, HC Wainwright decreased their price target on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $386.62.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.